#eGFR
LightNews LightNews
mathea-geraud.bsky.social
Glad to share our work in Science Advances on how targeted cancer therapy promotes the persistence of topoisomerase 1 cleavage complexes, which are involved in the emergence of resistance in lung cancer. Many thanks to Olivier Sordet's lab and to all co-authors. www.science.org/doi/10.1126/...
Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer
Resistance to targeted cancer therapies often arises from drug-tolerant cells, which survive treatment by entering a nonproliferative state. Over time, these cells can acquire mutations that contribut...
www.science.org
September 29, 2026 at 9:52 AM
drvergaro.bsky.social
(US20260274966A1) discloses a cetuximab–CD137 affibody bispecific designed to localise T-cell costimulation to EGFR+ tumours. Affinity optimisation improved CD137 EC50 to 0.092–0.128, but reduced purity in some formats. Key: EGFR-dependent agonism and systemic safety.
September 29, 2026 at 9:18 AM
2k115.bsky.social
AstraZeneca & HUTCHMED submitted a US NDA for all-oral ORPATHYS + TAGRISSO in EGFRm NSCLC with MET overexpression/amplification post-EGFR-TKI. Phase III SAFFRON trial reported improved survival vs chemotherapy; detailed results follow at ESMO 2026. Filing acceptance pending. #Pharma
AstraZeneca & HUTCHMED: Brief overview of the US FDA New Drug Application for the all-oral ORPATHYS + TAGRISSO combination in MET-driven, EGFR-mutated non-small cell lung cancer.
September 29, 2026 at 7:07 AM
2k115.bsky.social
AstraZeneca & HUTCHMED submitted a US NDA for all-oral ORPATHYS + TAGRISSO in EGFRm NSCLC with MET overexpression/amplification post-EGFR-TKI. Phase III SAFFRON trial reported improved survival vs chemotherapy; detailed results follow at ESMO 2026. Filing acceptance pending.
September 29, 2026 at 6:52 AM
cancerletter.com
Cancer Grand Challenges, through the Torrey Coast Foundation and Cancer Research UK, commits up to $34M to gastroesophageal cancer research
https://cancerletter.com/funding-opportunities/20260925_8a/
Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds - The Cancer Letter
Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared
cancerletter.com
September 28, 2026 at 10:00 PM
thebiotechtimes.bsky.social
J&J's amivantamab plus chemotherapy achieves 34.3-month median OS in EGFR Ex20ins lung cancer, per final PAPILLON Phase 3 data. The longest reported survival in this patient subset.
J&J's amivantamab plus chemo hits 34-month OS in EGFR Ex20ins NSCLC
Final PAPILLON Phase 3 data show a 34.3-month median overall survival with amivantamab plus chemotherapy, the longest reported in this historically difficult-to
biotech.disruptsmedia.com
September 28, 2026 at 6:00 PM
nautilus.bio
Drop by booth 228 at #HUPO2026 to explore a virtual model of the Nautilus Voyager™ Platform and discover how you can incorporate our AKT1 or EGFR proteoforms assays in your research free of charge through the Iterative Mapping Grant Program:

www.nautilus.bio/iterative-ma...
Iterative Mapping Grant Program ~ Nautilus Biotechnology
www.nautilus.bio
September 28, 2026 at 5:23 PM
ajkd.bsky.social
Carbamylation as a Novel Marker of Coronary Artery Calcification in People With CKD: Findings from a Phenome-Wide Association Study in CRIC

bit.ly/4xMU6VK
PheWAS results for continuous phenotypes. Each linear regression model uses the log-transformed and standardized carbamylated albumin (C-Alb) as the exposure and a log-transformed phenotype as the outcome, adjusted for age, sex, race and ethnicity, eGFR, and urinary protein. Effect sizes are shown as exponentiated beta coefficients, representing the proportional change (i.e., multiplicative effect or fold change) in the phenotype per 1 standard deviation increase in log-C-Alb. Panel A). Filled circles indicate statistical significance at the Benjamini–Yekutieli-corrected False Discovery Rate (FDR) threshold. Panel B) Displays only the significant continuous phenotypes. Abbreviations: SUN, serum urea nitrogen; LAD, left anterior descending; HDL, high density lipoprotein; MAP, Mean Arterial Pressure; CO2, Carbon dioxide; HA1C, Hemoglobin A1C, PLT, platelets; RBC, red blood cells; WBC, white blood cells; VLDL, very low-density lipoprotein.
September 28, 2026 at 4:01 PM
cancerletter.com
Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds
https://cancerletter.com/clinical-roundup/20260925_9a/
FDA approves Lyrfigtu for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma - The Cancer Letter
FDA granted approval for Lyrfigtu (lirafugratinib) as a treatment option for patients with cholangiocarcinoma with FGFR2
cancerletter.com
September 28, 2026 at 12:00 PM
mediadigital178.bsky.social
Find the Best Kidney Specialist in Delhi NCR with RIIMS. Dr. Abhishek Gupta reviews kidney reports, eGFR, urine protein, ultrasound and medical history, providing clear guidance with nephrology coordination when required.

riimshospitals.com/doctors/kidn...
Best Kidney Specialist in Delhi NCR | Kidney Specialist Doctor in Delhi NCR | Best Nephrologists in Delhi NCR - RIIMS Hospital Baraut
Looking for Best Kidney Specialist in Delhi NCR? Consult the Best Kidney Specialist in Delhi NCR at RIIMS Hospital Baraut. Expert kidney specialist doctors provide advanced treatment for kidney diseas...
riimshospitals.com
September 28, 2026 at 6:10 AM
mediadigital178.bsky.social
Looking for a Kidney Specialist in Delhi NCR? RIIMS Hospital personalized kidney care by reviewing creatinine, eGFR, urine protein, ultrasound, and medical history understand kidney health and guide appropriate treatment with nephrology coordination when needed.

riimshospitals.com/doctors/kidn...
Best Kidney Specialist in Delhi NCR | Kidney Specialist Doctor in Delhi NCR | Best Nephrologists in Delhi NCR - RIIMS Hospital Baraut
Looking for Best Kidney Specialist in Delhi NCR? Consult the Best Kidney Specialist in Delhi NCR at RIIMS Hospital Baraut. Expert kidney specialist doctors provide advanced treatment for kidney diseas...
riimshospitals.com
September 28, 2026 at 6:03 AM
chougenkai.bsky.social
あ～～～でも、すぐに決めずに他の選択肢見とけばな問題もあったな
EGFR変異解析がPOCTなわけあるか
September 28, 2026 at 4:49 AM
thebiotechtimes.bsky.social
Eledon's tegoprubart maintained a 13 mL/min eGFR advantage over tacrolimus at 24 months in Phase 2, with no rejections after month six. The data could reshape kidney transplant immunosuppression economics.
Eledon tegoprubart shows 13 mL/min eGFR edge over tacrolimus
Eledon's Phase 2 BESTOW extension data show tegoprubart maintained significantly better kidney function than tacrolimus at 24 months, with no rejections beyond six
biotech.disruptsmedia.com
September 27, 2026 at 6:27 PM
debatemx.bsky.social
Nunca fumaron y desarrollaron cáncer de pulmón: el hallazgo que explica por qué ocurre
Una mutación genética rara, identificada como EGFR T790M, puede aumentar hasta 25 veces el riesgo de cáncer de pulmón, según un estudio publicado en septiembre de 2026. El hallazgo, basado en el análisis de más de 3.3 millones de personas, podría cambiar la forma en que se realiza el cribado de esta enfermedad.
dlvr.it
September 27, 2026 at 5:19 PM
pritimrfr.bsky.social
Egfr-Antikörper-Marktgröße und zukünftiges Wachstum 2032 | WiseGuyReports www.wiseguyreports.com/de/reports/e...
Egfr-Antikörper-Marktgröße und zukünftiges Wachstum 2032
Es wird erwartet, dass die Marktgröße für Egfr-Antikörper von 4,14 Milliarden US-Dollar im Jahr 2024 auf 40,28 Milliarden US-Dollar im Jahr 2032 wachsen wird. Der Egfr-Antikörper Die Markt-CAGR (Wachs...
www.wiseguyreports.com
September 27, 2026 at 2:21 PM
dochill1982.bsky.social
Nice study and the big ticket result for me is the effects on eGFR slope of Sibeprenlimab compared to others. Would be interesting to add in dual inhibitors like Atacicept for comparison!
September 27, 2026 at 6:31 AM
buckeyemadison.bsky.social
This silent afib (silent until this week) may be the reason for my kidney issues. I may not even have it. The last blood they took from me before I went home showed my EGFR to be nearly normal. I have not seen numbers this good since they diagnosed the CKD a few years ago. My kidney….
September 26, 2026 at 11:43 PM
lieju.bsky.social
「健康カプセル！ゲンキの時間」、今日は腎臓。健康診断では覚えてないくらい昔から毎年腎機能軽度低下（eGFRの数値がちょっと足りない）と言われているので、見てる。
hicbc.com/tv/genki/

私の数値だと2/3しか働いてないらしい…。結局塩分か…。
健康カプセル！ゲンキの時間 | CBCテレビ | 日曜 午前7:00
ニッポンの皆様に健康生活を！この言葉をキーワードにすぐに役立つ健康情報をお伝えします。「人」「家族」の未来を創り出す、CBCテレビの健康情報番組。
hicbc.com
September 26, 2026 at 10:09 PM
asnpublications.bsky.social
Study in #ASNCJASN: In high-risk IgAN, RAAS inhibitors alone slowed eGFR decline to -4.5 mL/min/1.73 m² per year, well above the ≤1 mL/min/1.73 m² target needed to reduce ESKD risk, underscoring the need for disease-modifying therapies. kidney.pub/CJASN1130
September 26, 2026 at 4:30 PM
danafarber.bsky.social
Dana-Farber researchers in collaboration with 23andMe identified a rare genetic risk factor for lung cancer in people who have never smoked. The findings could help shape future screening strategies for people who carry the EGFR mutation. Read more in the @nytimes.com.
This Rare Gene Drastically Raises Lung Cancer Risk in People Who Never Smoked
The gene is found predominantly in Southern Appalachia and may be one of the most powerful cancer-risk mutations ever found.
bit.ly
September 26, 2026 at 3:45 PM
med-office-j.bsky.social
【わが国における健診発見尿蛋白「1＋」以上例のフォローアップ実態は？/KI Rep】Sep.25

日本、健診尿検査で「1＋」以上だった46.504例解析——

・半年以内に92%が医療機関受診。
・うち37%が再び「定性」検査。「定量」検査は4%。
・「定性」再施行率が低かった集団は「2＋以上」「eGFR低値」
　「DM」例。
・逆に再施行率「高」の集団としては「高血圧」例。

抄録🔗 x.gd/QbR4a
September 26, 2026 at 3:03 AM
thebiotechtimes.bsky.social
BlossomHill raised $168m in its Nasdaq IPO and secured FDA Fast Track for BH-30643, an EGFR C797S inhibitor in NSCLC. Capital and regulatory momentum converging.
BlossomHill raises $168m IPO and wins FDA Fast Track for BH-30643
BlossomHill Therapeutics completed a $168m Nasdaq IPO and secured FDA Fast Track designation for its EGFR C797S inhibitor BH-30643 in NSCLC.
biotech.disruptsmedia.com
September 26, 2026 at 12:00 AM
replaye.bsky.social
Never smoked a cigarette? You could still be at higher risk for lung cancer
replaye.com/never-smoked...

#News #Cigarette #Health #LungCancer #Cancer
Never smoked a cigarette? You could still be at higher risk for lung cancer - Replaye
Never-smokers carrying the rare EGFR T790M gene variant face 62 times the odds of lung cancer, a major study of 3.3 million people suggests.
replaye.com
September 25, 2026 at 7:20 PM
american-news-day.bsky.social
Never smoked a cigarette? You could still be at higher risk for lung cancer

https://fascinating.news/r/BIJP2MZT
Never smoked a cigarette? You could still be at higher risk for lung cancer
Never-smokers carrying the rare EGFR T790M gene variant face 62 times the odds of lung cancer, a major study of 3.3 million people suggests.
fascinating.news
September 25, 2026 at 6:32 PM
sigtrans-sttt.bsky.social
Findings from a randomized phase III #ClinicalTrial showed that mefatinib improved progression-free survival vs gefitinib, with a pronounced benefit in #EGFR L858R-mutated #NSCLC and comparable outcomes in exon 19 deletion.

#STTT #OpenAccess: doi.org/10.1038/s413...
Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study
September 25, 2026 at 12:15 PM